Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-011003
Filing Date
2025-03-20
Accepted
2025-03-20 11:33:48
Documents
78
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1182587
2 ex10-1.htm EX-10.1 220985
3 ex10-2.htm EX-10.2 155060
4 ex10-3.htm EX-10.3 140680
5 ex10-4.htm EX-10.4 187680
6 ex10-5.htm EX-10.5 114536
7 ex31-1.htm EX-31.1 13029
8 ex31-2.htm EX-31.2 13541
9 ex32-1.htm EX-32.1 6624
10 ex32-2.htm EX-32.2 7151
  Complete submission text file 0001493152-25-011003.txt   8406586

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE vtro-20250131.xsd EX-101.SCH 60693
12 XBRL CALCULATION FILE vtro-20250131_cal.xml EX-101.CAL 77738
13 XBRL DEFINITION FILE vtro-20250131_def.xml EX-101.DEF 249326
14 XBRL LABEL FILE vtro-20250131_lab.xml EX-101.LAB 492319
15 XBRL PRESENTATION FILE vtro-20250131_pre.xml EX-101.PRE 366138
81 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1181690
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

EIN.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41766 | Film No.: 25755024
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)